MLchartDataset catalogue

Provenge

Term · Oncology and biomedicine · MLC-T-ONC-007024

A vaccine used to treat prostate cancer that has spread to other parts of the body. It is used in patients who have few or no symptoms and whose cancer is castration resistant (has not responded to treatments that lower testosterone levels). Provenge is made from a patient’s immune cells that have been treated in the laboratory with GM-CSF (a type of growth factor) and a protein found on prostate cancer cells. Provenge may help the immune system kill prostate cancer cells. It is a type of autologous cellular immunotherapy and a type of dendritic cell vaccine. Also called APC 8015 and sipuleucel-T.

Table 1. Record
IdentifierMLC-T-ONC-007024
FieldOncology and biomedicine
SynonymsAPC 8015; sipuleucel-T
ReferencesNCI Dictionary of Cancer Terms
Record as JSON
{
  "id": "MLC-T-ONC-007024",
  "term": "Provenge",
  "field": "Oncology and biomedicine",
  "definition": "A vaccine used to treat prostate cancer that has spread to other parts of the body. It is used in patients who have few or no symptoms and whose cancer is castration resistant (has not responded to treatments that lower testosterone levels). Provenge is made from a patient’s immune cells that have been treated in the laboratory with GM-CSF (a type of growth factor) and a protein found on prostate cancer cells. Provenge may help the immune system kill prostate cancer cells. It is a type of autologous cellular immunotherapy and a type of dendritic cell vaccine. Also called APC 8015 and sipuleucel-T.",
  "synonyms": [
    "APC 8015",
    "sipuleucel-T"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms"
  ],
  "url": "https://mlchart.com/terminology/oncology/provenge/"
}

Record 13,782 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.